Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide
Identifieur interne : 001E85 ( Istex/Curation ); précédent : 001E84; suivant : 001E86Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide
Auteurs : Joseph F. Lipinski [États-Unis] ; Sallee [États-Unis] ; Cherry Jackson [États-Unis] ; Gopalan Sethuraman [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1997-05.
English descriptors
Abstract
This exploratory study was meant to determine the effect of the dopamine (DA) agonist pergolide on Gilles de la Tourette syndrome (GTS) in children and adolescents and to ascertain correlates of pergolide response. Thirty‐two outpatients, aged 7–19 years, were systematically assessed in a neuropsychiatric clinic for the presence of GTS and comorbid disorders. After a 6‐week open‐label, fixed‐flexible dosing schedule, response to pergolide on standard GTS severity outcome measures was assessed. Overall, 75% of patients (24/32) had a >50% drop in their tic severity rating from baseline with a mean treatment dosage of 177 ± 61 μg/day. Highly significant (p = 0.0001) baseline to week 6 differences were demonstrated in all tic symptom measures. The presence of restless legs syndrome (RLS) comorbidity (59%) was highly associated with a positive response. These results suggest DA agonism as a strategy, and pergolide in particular, may be a practical form of therapy for GTS. Response predictors of patient comorbid RLS argue for its further study with regard to GTS.
Url:
DOI: 10.1002/mds.870120320
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001E85
Links to Exploration step
ISTEX:428DD79A028678FDF19C66EB4B09C9E7E02C61FCLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide</title><author><name sortKey="Lipinski, Joseph F" sort="Lipinski, Joseph F" uniqKey="Lipinski J" first="Joseph F." last="Lipinski">Joseph F. Lipinski</name><affiliation wicri:level="1"><mods:affiliation>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Sallee" sort="Sallee" uniqKey="Sallee" last="Sallee">Sallee</name><affiliation wicri:level="1"><mods:affiliation>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, Cherry" sort="Jackson, Cherry" uniqKey="Jackson C" first="Cherry" last="Jackson">Cherry Jackson</name><affiliation wicri:level="1"><mods:affiliation>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Sethuraman, Gopalan" sort="Sethuraman, Gopalan" uniqKey="Sethuraman G" first="Gopalan" last="Sethuraman">Gopalan Sethuraman</name><affiliation wicri:level="1"><mods:affiliation>Departments of Biometry and Biostatistics, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Biometry and Biostatistics, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:428DD79A028678FDF19C66EB4B09C9E7E02C61FC</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1002/mds.870120320</idno><idno type="url">https://api.istex.fr/document/428DD79A028678FDF19C66EB4B09C9E7E02C61FC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E85</idno><idno type="wicri:Area/Istex/Curation">001E85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide</title><author><name sortKey="Lipinski, Joseph F" sort="Lipinski, Joseph F" uniqKey="Lipinski J" first="Joseph F." last="Lipinski">Joseph F. Lipinski</name><affiliation wicri:level="1"><mods:affiliation>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Sallee" sort="Sallee" uniqKey="Sallee" last="Sallee">Sallee</name><affiliation wicri:level="1"><mods:affiliation>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Jackson, Cherry" sort="Jackson, Cherry" uniqKey="Jackson C" first="Cherry" last="Jackson">Cherry Jackson</name><affiliation wicri:level="1"><mods:affiliation>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Psychiatry, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author><author><name sortKey="Sethuraman, Gopalan" sort="Sethuraman, Gopalan" uniqKey="Sethuraman G" first="Gopalan" last="Sethuraman">Gopalan Sethuraman</name><affiliation wicri:level="1"><mods:affiliation>Departments of Biometry and Biostatistics, Medical University of South Carolina, Charleston, South Carolina, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Biometry and Biostatistics, Medical University of South Carolina, Charleston, South Carolina</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1997-05">1997-05</date><biblScope unit="vol">12</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="402">402</biblScope><biblScope unit="page" to="407">407</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">428DD79A028678FDF19C66EB4B09C9E7E02C61FC</idno><idno type="DOI">10.1002/mds.870120320</idno><idno type="ArticleID">MDS870120320</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine agonists</term><term>Pergolide</term><term>Restless legs syndrome</term><term>Tourette syndrome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This exploratory study was meant to determine the effect of the dopamine (DA) agonist pergolide on Gilles de la Tourette syndrome (GTS) in children and adolescents and to ascertain correlates of pergolide response. Thirty‐two outpatients, aged 7–19 years, were systematically assessed in a neuropsychiatric clinic for the presence of GTS and comorbid disorders. After a 6‐week open‐label, fixed‐flexible dosing schedule, response to pergolide on standard GTS severity outcome measures was assessed. Overall, 75% of patients (24/32) had a >50% drop in their tic severity rating from baseline with a mean treatment dosage of 177 ± 61 μg/day. Highly significant (p = 0.0001) baseline to week 6 differences were demonstrated in all tic symptom measures. The presence of restless legs syndrome (RLS) comorbidity (59%) was highly associated with a positive response. These results suggest DA agonism as a strategy, and pergolide in particular, may be a practical form of therapy for GTS. Response predictors of patient comorbid RLS argue for its further study with regard to GTS.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E85 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 001E85 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:428DD79A028678FDF19C66EB4B09C9E7E02C61FC
|texte= Dopamine agonist treatment of tourette disorder in children: Results of an open‐label trial of pergolide
}}
| This area was generated with Dilib version V0.6.23. |  |